Last reviewed · How we verify
LASW1835
LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels.
LASW1835 is a selective inhibitor of phosphodiesterase 4 (PDE4) that reduces inflammatory mediator production by increasing intracellular cAMP levels. Used for Chronic obstructive pulmonary disease (COPD), Asthma.
At a glance
| Generic name | LASW1835 |
|---|---|
| Also known as | Fumaderm initial/ Fumaderm |
| Sponsor | Almirall, S.A. |
| Drug class | PDE4 inhibitor |
| Target | PDE4 |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | Phase 3 |
Mechanism of action
PDE4 inhibition leads to accumulation of cyclic adenosine monophosphate (cAMP) in immune and inflammatory cells, suppressing the release of pro-inflammatory cytokines and chemokines. This mechanism is intended to reduce airway inflammation and improve lung function in inflammatory airway diseases. The drug is being developed for respiratory indications where PDE4-mediated inflammation plays a pathogenic role.
Approved indications
- Chronic obstructive pulmonary disease (COPD)
- Asthma
Common side effects
- Nausea
- Diarrhea
- Headache
- Tremor
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LASW1835 CI brief — competitive landscape report
- LASW1835 updates RSS · CI watch RSS
- Almirall, S.A. portfolio CI